Brendan Smith - Oct 14, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Oct 14, 2022
Transactions value $
-$61,949
Form type
4
Date filed
10/18/2022, 05:38 PM
Previous filing
Oct 12, 2022
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +3.75K 3.75K Oct 14, 2022 Direct F1, F2
transaction CRSP Common Shares Tax liability -$61.9K -1.11K -29.63% $55.76 2.64K Oct 17, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise +3.75K +50% 11.3K Oct 14, 2022 Common Shares 3.75K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on October 14, 2022, (ii) one quarter of the shares shall vest on October 14, 2023, (iii) one quarter of the shares shall vest on October 14, 2024, and (iv) one quarter of the shares shall vest on October 14, 2025.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 On October 14, 2021, the reporting person was granted 15,000 restricted stock units. On October 14, 2022, 3,750 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.